| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Vaccines | Infectious Diseases | ||
Phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Vaccines | Infectious Diseases | ||
Phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Vaccines | Infectious Diseases |
Recent Updates
Recently added Catalysts
LakeShore Biopharma Co., Ltd$0.63
-0.16 (-20.62%)
C 42Pipeline Score Overvalued Biotech · Clinical
Market Cap
25.84 M
EPS
-
P/E Ratio
-
Value Trade
613.76 K
-26.24 %
Week
-20.64 %
1 Month
-32.58 %
3 Month
-71.24 %
6 Month
-99.34 %
5 Year
-99.34 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
942.22 K
52 Week Range
0.57 - 8.60
% held by Insiders
82.69 %
% held by Institutions
6.24 %
Enterprise Value
68.60 M
Total Shares
41.21 M
Short %
0.24 %
Float Shares
4.96 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
C42
Pipeline Score $13M
Pipeline ValueOvervalued
Valuation Signal3
Drugs Scored0.5x
rNPV / MCap Top 60%
Micro Cap (rank 363 of 906)
Percentile RankLakeShore Biopharma Co., Ltd carries a moderate pipeline score (42/100), with $3.2B risk-adjusted pipeline value, led by PIKA COVID-19 vaccine in Covid-19 Vaccine (Phase 2), across $51B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PIKA COVID-19 vaccine Monoclonal antibody | Covid-19 Vaccine | Phase 2 | NCT05463419 | 30% | $3.1B | COMPLETED | 5,860 | - | - | Apr 11, 2024 | - | Jul 23, 2024 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
PIKA Rabies Vaccine | rabies virus infection | Phase 3 | 2024-04-09 | RVNA seroconversion rate: twice that of the comparator by Day 7 Read More | YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine GAITHERSBURG, Md. Read More | |
PIKA Rabies Vaccine | rabies virus infection | Phase 3 | 2024-04-09 | RVNA seroconversion rate: twice that of the comparator by Day 7 Read More | YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine GAITHERSBURG, Md. Read More | |
PIKA Rabies Vaccine | rabies virus infection | Phase 3 | 2024-04-09 | RVNA seroconversion rate: twice that of the comparator by Day 7 Read More | YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine GAITHERSBURG, Md. Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in LSB
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
LSB Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How LSB ranks across every disease it competes inCompetitive Position is a premium feature
See how LSB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial